The stock of 3D Signatures Inc (CVE:DXD) is a huge mover today! About 60,800 shares traded hands. 3D Signatures Inc (CVE:DXD) has risen 6.00% since September 17, 2016 and is uptrending. It has outperformed by 0.39% the S&P500.
The move comes after 7 months positive chart setup for the $23.85M company. It was reported on Oct, 17 by Barchart.com. We have $0.86 PT which if reached, will make CVE:DXD worth $11.69 million more.
More notable recent 3D Signatures Inc (CVE:DXD) news were published by: Finance.Yahoo.com which released: “3D Signatures Inc. Appoints Jason Flowerday as New CEO” on September 27, 2016, also Marketwired.com with their article: “3D Signatures Inc. Announces Closing of Qualifying Transaction” published on September 09, 2016, Marketwired.com published: “3D Signatures Inc. Commences Trading September 13th Under the Symbol (TSX …” on September 12, 2016. More interesting news about 3D Signatures Inc (CVE:DXD) were released by: Marketwatch.com and their article: “3D Signatures Inc. Announces Grant of Stock Options” published on September 26, 2016 as well as Marketwired.com‘s news article titled: “3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and …” with publication date: May 26, 2016.
3D Signatures Inc, formerly Plicit Capital Corp, is a Canada personalized medicine firm with a software platform based on the three-dimensional analysis of telomere organization. The company has a market cap of $23.85 million. The Company’s software technology and prognostic methodology targets various diseases that demonstrate genomic instability, including cancer and neurological disorders. It currently has negative earnings. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including 3D Telo-PC, 3D Telo-RS, 3D Telo-MM, 3D Telo-BC, 3D Telo-LC and 3D Telo-AD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.